No CrossRef data available.
Article contents
P0010 - Naltrexone implants: Can they prevent relapse into heroine use?
Published online by Cambridge University Press: 16 April 2020
Abstract
The Miroya Foundation specializes in Anesthesia Assisted Rapid Opiate Detoxification (AAROD) for opiate addiction. After psychosocial and medical intake patients are hospitalized for 24hours for AAROD. A subcutaneous naltrexone implant is inserted. We start with an 8week implant and advise patients to use 6months Naltrexone implants for at least one year. We prescribe Naltrexone tablets to patients who cannot afford implants. All patients are offered one year psychotherapy.
To evaluate the effectiveness and risks of Naltrexone Implants.
Retrospective descriptive study of all patients with naltrexone implants.
July 2007 there were 159 Naltrexone implants used in 80 patients. 26 patients are in the first year of treatment with a 1st, 2nd or 3rd implant. 3 patients used heroine while having an effective implant. 54 patients finished the treatment year.
Reason for stopping Naltrexone implant treatment in 54 patients:
159 implants used in 80 patients.. Only 1 severe complication occurred. Relapse rate in 80 patients 3,75% suggests that naltrexone implants are very effective. Most common reason for stopping use of naltrexone implant: lack of money 46%.
Table 1
Severe | Severe infection, implant removed (psychiatric patient, history of auto mutilation) | 1 | 1.25% |
Minor | Withdrawal symptoms after insertion | 1 | 1.25% |
Infection suspected, antibiotics prescribed | 5 | 6.25% | |
Itching | 4 | 5% | |
Swelling | 20 | 25% |
Reason for stopping Naltrexone implant treatment in 54 patients | Nr of Patients | ||
---|---|---|---|
End of treatment year | 17 | 31% | |
No money for next implant | 25 | 46% | |
Complications | 2 | 3% | |
Cosmetic reasons | 2 | 3% | |
Relapse, not coming back for next implant | 9 | 16% | |
Reason unknown | 6 | 11% |
- Type
- Poster Session III: Alcoholism And Addiction
- Information
- European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S306 - S307
- Copyright
- Copyright © European Psychiatric Association 2008
Comments
No Comments have been published for this article.